Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening

被引:39
|
作者
Chen, Yufeng [1 ,2 ,3 ]
Zhao, Weilin [1 ,6 ]
Lin, Longde [2 ,3 ]
Xiao, Xue [1 ]
Zhou, Xiaoying [1 ]
Ming, Huixin [1 ]
Huang, Tingting [1 ,2 ]
Liao, Jian [4 ]
Li, Yancheng [4 ]
Zeng, Xiaoyun [2 ,3 ]
Huang, Guangwu [1 ,2 ]
Ye, Weimin [5 ]
Zhang, Zhe [1 ,2 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Nanning, Guangxi, Peoples R China
[2] Guangxi Med Univ, Minist Educ, Key Lab High Incidence Tumor Prevent & Treatment, Nanning, Guangxi, Peoples R China
[3] Guangxi Med Univ, Sch Publ Hlth, Dept Epidemiol, Nanning, Guangxi, Peoples R China
[4] Canc Inst Cangwu Cty, Wuzhou, Guangxi, Peoples R China
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] Mie Univ, Grad Sch Med, Dept Environm & Mol Med, Tsu, Mie, Japan
来源
PLOS ONE | 2015年 / 10卷 / 07期
关键词
DNA LOAD; PLASMA; EBV; BRUSHINGS; INFECTION; DIAGNOSIS; BLOOD; GENE;
D O I
10.1371/journal.pone.0132669
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Serological detection of Epstein-Barr virus (EBV) antibodies is frequently used in nasopharyngeal carcinoma (NPC) mass screening. However, the large number of seropositive subjects who require close follow-up is still a big burden. The present study aimed to detect the nasopharyngeal EBV load in a high-risk population seropositive for antibodies against EBV, as well as to examine whether assay for nasopharyngeal EBV DNA load might reduce the number of high-risk subjects for follow-up and improve early detection of NPC. A prospective and population-based cohort study was conducted in southern China from 2006 through 2013. Among 22,186 participants, 1045 subjects with serum immunoglobulin A (IgA) antibodies against viral capsid antigen (VCA) titers >= 1: 5 were defined as high-risk group, and were then followed-up for NPC occurrence. Qualified nasopharyngeal swab specimens were available from 905 participants and used for quantitative PCR assay. Our study revealed that 89% (802/905) subjects showed positive EBV DNA in nasopharyngeal swab. The nasopharyngeal EBV load in females was higher than that in males. The nasopharyngeal EBV load increased with increasing serum VCA/IgA titers. Eight cases of newly diagnosed NPC showed an extremely elevated EBV load, and 87.5% (7 of 8 patients) were early-stage NPCs. The EBV loads of 8 NPCs were significantly higher than those of 897 NPC-free subjects (mean, 2.8x10(6) copies/swab [range 4.8x10(4)-1.1x10(8)] vs. 5.6x10(3) [range 0-3.8x10(6)]). Using mean EBV load in NPC-free population plus two standard deviations as cut-off value, a higher diagnostic performance was obtained for EBV load test than serum VCA/IgA test (area under ROC, 0.980 vs 0.895). In conclusion, in a prospective and population-based study we demonstrated that an additional assay of EBV load in the nasopharynx among high-risk individuals may reduce the number of subjects needed to be closely followed up and could serve as part of a NPC screening program in high-risk populations.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma
    Tay, Joshua K.
    Chan, Soh Ha
    Lim, Chwee Ming
    Siow, Chor Hiang
    Goh, Han Lee
    Loh, Kwok Seng
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2016, 155 (02) : 274 - 280
  • [2] Epstein-Barr virus and nasopharyngeal carcinoma
    Lawrence SYoung
    Christopher WDawson
    ChineseJournalofCancer, 2014, 33 (12) : 581 - 590
  • [3] Epstein-Barr virus and nasopharyngeal carcinoma
    Young, Lawrence S.
    Dawson, Christopher W.
    CHINESE JOURNAL OF CANCER, 2014, 33 (12) : 581 - 590
  • [4] The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
    Li, You Quan
    Khin, Ni Sann
    Chua, Melvin L. K.
    CANCER BIOLOGY & MEDICINE, 2018, 15 (01) : 1 - 5
  • [5] Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment
    Adham, Marlinda
    Greijer, Astrid E.
    Verkuijlen, Sandra A. W. M.
    Juwana, Hedy
    Fleig, Sabine
    Rachmadi, Lisnawati
    Malik, Octavia
    Kurniawan, A. N.
    Roezin, Averdi
    Gondhowiardjo, Soehartati
    Atmakusumah, Djumhana
    Stevens, Servi J. C.
    Hermani, Bambang
    Tan, I. Bing
    Middeldorp, Jaap M.
    CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2175 - 2186
  • [6] Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China
    Zheng, Xiao-Hui
    Lu, Li-Xia
    Li, Xi-Zhao
    Jia, Wei-Hua
    CANCER SCIENCE, 2015, 106 (09) : 1196 - 1201
  • [7] Evaluation of nasal and nasopharyngeal swab collection for the detection of Epstein-Barr virus in nasopharyngeal carcinoma
    Coghill, Anna E.
    Wang, Cheng-Ping
    Verkuijilen, Sandra A. W. M.
    Yu, Kelly J.
    Hsu, Wan-Lun
    Middeldorp, Jaap M.
    Hildesheim, Allan
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (01) : 191 - 195
  • [8] Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia
    Baizig, Nehla Mokni
    Morand, Patrice
    Seigneurin, Jean Marie
    Boussen, Hamouda
    Fourati, Asma
    Gritli, Said
    Oueslati, Zeineb
    Touati, Slim
    Gamoudi, Amor
    Ben Abdallah, Mansour
    El May, Michele
    El May, Ahmed
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2012, 269 (03) : 1005 - 1011
  • [9] Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma
    Stoker, Sharon D.
    Novalic, Zlata
    Wildeman, Maarten A.
    Huitema, Alwin D. R.
    Verkuijlen, Sandra A. W. M.
    Juwana, Hedy
    Greijer, Astrid E.
    Tan, I. Bing
    Middeldorp, Jaap M.
    de Boer, Jan Paul
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (10) : 1845 - 1857
  • [10] Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis
    Richardo, Timmy
    Prattapong, Pongphol
    Ngernsombat, Chawalit
    Wisetyaningsih, Nurulfitri
    Iizasa, Hisashi
    Yoshiyama, Hironori
    Janvilisri, Tavan
    CANCERS, 2020, 12 (09) : 1 - 23